At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 58 enrolled
Drug / intervention
Sertraline +2 moredrug
Likely dose
Sertraline 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Rhodiola Rosea Therapy of Major Depressive Disorder
In Brief
A Phase 3 clinical trial evaluating Herbal extract, Sertraline, and 1 other intervention for Depression. Completed, enrolled 58 participants across 1 site.
Detailed Summary
Prior research has shown that Rhodiola rosea may be an effective, short-term, anti-depressant therapy. This study will examine the anti-depressant effect of Rhodiola rosea vs. a conventional, anti-depressant drug in the treatment of major depression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
CountriesUnited States
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2010
Enrollment StartJun 2010
Primary CompletionJul 2013
TodayJul 2026
First PostedApr 2, 2010
Enrollment StartJun 1, 2010
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 16.3 years ago
Interventions
Herbal extractdietary
340-1,360 mg daily
Sertralinedrug
50-200 mg daily
Lactose monohydrateother
1-4 capsules daily